Skip to main content

Table 1 Effects of MR16-1 on cancer-related symptoms in the LC-06-JCK mouse model

From: Treatment with anti-IL-6 receptor antibody prevented increase in serum hepcidin levels and improved anemia in mice inoculated with IL-6–producing lung carcinoma cells

 

0 weeks

5 weeks

 

NTB

TB

NTB

TB

MR16-1

Body weight (g)

25.5 ± 1.4

25.8 ± 1.3

28.0 ± 1.1

24.5 ± 2.0*

25.9 ± 2.0**

Albumin (mg/mL)

28.9 ± 3.0

26.5 ± 5.1*

25.5 ± 3.8

16.7 ± 2.6*

22.1 ± 2.8**

SAA (μg/mL)

60.7 ± 95.7

589.2 ± 614.8*

24.8 ± 12.7

5638.0 ± 2867.5*

353.0 ± 302.9**

Tumor volume (mm3)

ND

143.9 ± 43.0

ND

1369.9 ± 301.5

1647.6 ± 515.8

  1. Body weight, serum albumin levels, SAA levels, and tumor volumes were measured in mice before treatment (0 weeks) and after being treated for 5 weeks. Results are the mean ± SD for 19–20 mice in each group. *P < 0.05, age-matched NTB group versus TB group (Wilcoxon test); **P < 0.05, TB group versus MR16-1 group (Wilcoxon test)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us